Short answer
Option Care Health, Inc. (OPCH) filed its fiscal 2025 10-K annual report with the SEC on Feb 24, 2026. It reported revenue of $5.6B (+15.0% year over year) and net income of $208M.
FY2025 key financial metrics · XBRL
- Revenue
- $5.6B
- +15.0% YoY
- Net income
- $208M
- −2.0% YoY
- Operating margin
- 6.0%
- −0.6 pp YoY
- Gross margin
- 19.3%
- −1.4 pp YoY
- EPS (diluted)
- $1.27
- +3.3% YoY
- ROE
- 15.7%
- +0.6 pp YoY
- Operating cash flow
- $258M
- −20.1% YoY
Source: XBRL data from the Option Care Health, Inc. (OPCH) FY2025 10-K on SEC EDGAR. USD.
Option Care Health, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Largest independent provider of home and alternate site infusion therapy via 196 locations in 43 states, serving complex chronic conditions
- New emphasis: Expansion of ambulatory infusion suites to 109 standalone locations, including 27 with advanced practitioner capabilities
- Strategic position: Strengthened national presence with integrated sales targeting managed care, health systems, and drug manufacturers for new product launches
- Quantitative metric: Employee count rose to 6,528 full-time and 1,738 part-time as of Dec 31, 2025, including ~2,700 nursing staff
- Noteworthy fact: Received multiple national accreditations (ACHC, PCAB, ASHP, URAC) underscoring quality and compliance in infusion services
Management Discussion & Analysis
- Revenue $5.65B, up 13.0% YoY from $5.00B driven by mid-teens growth in acute therapies and low double-digit chronic growth
- Operating margin declined to 6.0% from 6.4%; gross margin fell to 19.3% from 20.3% due to therapy mix and biosimilar adoption
- Best segment: Acute therapies with mid-teens revenue growth; Worst: Chronic therapies with higher cost mix including rare/orphan therapies
- Operating cash flow $258M down $65M; investing cash outflow $161M up $125M due to Intramed Plus acquisition; financing cash outflow $277M up $59M driven by $310M stock repurchase
- Management expects $25M-$35M negative gross profit impact in 2026; secured credit facility amendments lowered interest rate and extended maturities supporting liquidity
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.